Seoul Bio Hub

Name

Seoul Bio Hub

Legal name

Seoul Bio Hub (서울바이오허브)

Website

https://seoulbiohub.kr

Company type

Private

Founded year

2017

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biotech Startup Incubation and Innovation Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biotech startup incubation
• Open innovation programs
• Biotech accelerator services
• Shared research infrastructure
• Global pharma partnerships

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Government funding and public grants: Seoul Bio Hub is operated as a public innovation platform funded by Seoul Metropolitan City and hosted by Korea Institute of Science and Technology (KIST) and Korea University. The hub's programs and operations are supported by government budget allocations, with some programs co-funded by pharmaceutical partners.
2. Facility rental and tenant services: The hub generates revenue through renting office and laboratory space to resident biotech startups. Facilities include independent spaces, open-plan desks, and shared research equipment.
3. Program participation fees: Startups participating in open innovation programs receive research grants from co-organizing pharmaceutical partners and Seoul Bio Hub, but may pay nominal participation or administrative fees for program access.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Seoul Bio Hub operates a publicly funded biotech startup incubation and open innovation platform that provides resident office and laboratory space, shared research equipment access through its TREE management system, and co-organized innovation programs with global pharmaceutical companies. It supports early-stage biotech, medical device, digital health, AI, and antibody drug startups through research grants (30-40 million KRW), mentoring, acceleration bootcamps including Silicon Valley programs, and direct pathways to global pharma partnerships for technology commercialization and international market entry.

Product overview

Seoul Bio Hub operates as a unified biotech startup innovation platform centered at the Hongneung bio cluster in Seoul, South Korea. The platform combines multiple service modules: open innovation programs (with BMS, Roche Diagnostics, Novartis, Celltrion, AstraZeneca, Samsung Bioepis), the TREE research infrastructure management system, and comprehensive startup support services including mentorship, funding access, and global expansion assistance. The core platform is augmented by specialized programs including the 2026 Seoul-BMS Innovation Square Challenge, 2026 Health X-Challenge Seoul (with Novartis), and the 2026 Seoul-Roche Diagnostics Startup Sprint Demo Day, which collectively form an integrated ecosystem supporting biotech startups from ideation through global commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• TREE (Total Research Equipment & Environment) Integrated Management System Web-based research infrastructure management platform providing integrated access to Seoul Bio Hub's equipment reservation, facility booking, education/seminar registration, and material import applications for tenant startup operations.
• 2026 Seoul-Roche Diagnostics Startup Sprint Demo Day Open innovation program partnering with Roche Diagnostics Korea and APAC to identify promising medical device and digital health startups. Provides 30 million KRW research funding, 1-year office space, and collaboration opportunities with Roche Diagnostics for global market expansion.
• 2026 Seoul-BMS Innovation Square Challenge Open innovation competition co-organized with Bristol Myers Squibb Korea and Seoul Metropolitan Government. Awards two selected startups with 40 million KRW each in research funding, plus BMS headquarters mentoring, global network access, and Seoul Bio Hub membership benefits across cell/gene therapy and antibody-drug conjugates categories.
• 2026 Health X-Challenge Seoul Digital healthcare open innovation program in partnership with Novartis Korea. Selects two companies receiving 40 million KRW research funding, Novartis expert mentoring and coaching, international network formation, and collaborative R&D opportunities focused on intelligent patient orchestration platforms.
• 2026 Seoul Bio Hub-Korea Technology Guarantee Fund Global Expansion Growth Acceleration Program Consulting and support program for Seoul-based bio/medical startups established within 10 years, focused on global market expansion. Combines Seoul Bio Hub's startup support ecosystem with Korea Technology Guarantee Fund's financing capabilities.
• Celltrion Open Innovation Program Multi-cohort open innovation partnership identifying early-stage biotech companies with technologies complementing Celltrion's R&D efforts. Provides mentoring, joint research opportunities, and business collaboration. Previous cohort companies have secured investments and research partnerships with Celltrion.
• Korea AstraZeneca-Seoul Bio Hub Global Open Innovation Program Joint incubation program providing 12 months of mentoring from AstraZeneca global research teams, eligibility for Sweden's Gothenburg BioVenture Hub, workspace support, and 35 million KRW research funding per selected startup.
• DHP Silicon Valley Bootcamp Three-month acceleration program conducted in partnership with Digital Healthcare Partners and Outsome accelerator. Supports Korean digital healthcare companies' global expansion through pre-mentoring in Korea, intensive two-week Silicon Valley training, and post-mentoring resulting in investment proposals, clinical contracts, and distribution agreements.
• Seoul Biohub-Samsung Bioepis Open Innovation Initiative First open innovation initiative between Seoul Biohub and Samsung Bioepis aimed at fostering AI and antibody drug startups. Program focuses on identifying and supporting early-stage companies in artificial intelligence applications and antibody drug development.
• Seoul Bio Hub-Celltrion Global Open Innovation Program 2025 Global open innovation program helping U.S.-based bio/medical startups established within seven years enter the Asian market. Selected companies receive tailored support and opportunities to collaborate with Celltrion, leveraging South Korea's clinical infrastructure and pharmaceutical capabilities.

Quantifiable outcome

• 8 startup companies from Seoul Biohub achieved global partnership results at BIO USA 2026
• +3 more outcomes

Named customers20 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Partnerships

14 partnerships are on record, tiered core and minor.

• CelltrioncoreStrategic or Co-development Partner · 10 June 2026Celltrion partners with Seoul Bio Hub for the Open Innovation Program, selecting 4 biotech startups per cohort to identify early-stage companies with technologies complementing Celltrion's R&D. The program provides mentoring and joint research opportunities. Previous cohort companies (Enterobiome, Biomi) secured investments and research partnerships with Celltrion. The 4th cohort (2026) includes AinB, Enbiocell, Imita Science, and Podo Therapeutics. An agreement-signing ceremony was held at Celltrion's Global Life Science Research Center in Songdo, Incheon.
• Novartis KoreacoreStrategic or Co-development Partner · 8 June 2026KIST Seoul Bio Hub and Novartis Korea co-organize the Health X-Challenge Seoul 2026 program, selecting 2 startups to receive 40 million KRW research funding each, Novartis expert mentoring and coaching, international networking, and joint R&D with Novartis Korea, plus 1-year office space and Seoul Bio Hub program benefits. Focus areas include intelligent patient orchestration platforms, AI-driven patient navigation, and interoperable data ecosystems targeting chronic and severe diseases (cardiovascular, immunology, oncology).
• BMS KoreacoreStrategic or Co-development Partner · 1 June 2026BMS Korea co-organizes the annual Seoul-BMS Innovation Challenge with Seoul Metropolitan Government and Seoul Bio Hub. The 2026 program (5th edition) awards two selected Korean biotech or healthcare startups with 40 million KRW (~$26,597) each in research funding across 12 categories spanning 5 therapeutic areas and 7 cross-cutting technology fields. Over four years, the initiative has supported eight Korean startups with access to BMS's global R&D expertise and network for follow-on investments and international partnerships.
• Roche DiagnosticscoreStrategic or Co-development Partner · 1 June 2026Seoul Bio Hub and Roche Diagnostics (Korea, APAC) co-organize the Seoul-Roche Diagnostics Startup Sprint Demo Day, selecting 1 startup to receive 30 million KRW in research funding, 1-year office space, access to Roche Diagnostics experts for partnering and networking, and support for global expansion. The 2026 program focuses on 4 topics: screening and preventive health, PCR portfolio expansion, patient-initiated testing (DaaS), and digital pathology. Operated in partnership with KMDF and Electronic News.
• Digital Healthcare PartnersminorStrategic or Co-development Partner · 23 March 2026Digital Healthcare Partners (DHP), a Korean investment firm specializing in digital healthcare startups, partnered with Seoul Bio Hub and Outsome accelerator for the DHP Silicon Valley Bootcamp 2026 — a 3-month acceleration initiative supporting Korean digital healthcare companies' global expansion. Seven selected startups underwent pre-mentoring in Korea, 2-week intensive training in Silicon Valley, and post-mentoring, resulting in investment proposals from U.S. investors, clinical contracts, and distribution channel agreements.
• AstraZenecacoreStrategic or Co-development PartnerKorea AstraZeneca and Seoul Bio Hub run the Global Open Innovation program, selecting two winning startups per cycle to receive 12 months of mentoring from AstraZeneca's global research teams, eligibility to join Sweden's Gothenburg BioVenture Hub, workspace support, and 35 million KRW ($23,877) in research funding each. The 2025 cycle selected Aavatar Therapeutics and Curogen from a pool of 33 applicants. The joint incubation agreement was signed in October 2024.
• Samsung BioepiscoreStrategic or Co-development PartnerSeoul Bio Hub and Samsung Bioepis launched their first open innovation initiative in May 2026, aimed at fostering AI and antibody drug startups. The program seeks to identify and support early-stage companies with technologies in artificial intelligence applications and antibody drug development that align with Samsung Bioepis's R&D pipeline.
• SK BiopharmminorStrategic or Co-development PartnerSK Biopharm partnered with Seoul Bio Hub for Open Innovation Phase 1, selecting 2 companies and signing agreements. Details of the program scope and selected companies are limited.
• Kibo (Technology Guarantee Fund)coreStrategic or Co-development PartnerKibo (Korea Technology Finance Corporation / 기술보증기금) and Seoul Bio Hub collaborate on the Global Growth Acceleration Program to support global commercialization of bio startups. The 2026 program provides consulting, mentorship, and export support services for Seoul-based bio/medical startups established within 10 years. The program ran from June 4 to July 8, 2026.
• Korea Institute of Science and Technology (KIST)coreImplementation/ SI/ Consulting PartnerKIST is one of the two operating institutions of Seoul Bio Hub (alongside Korea University). KIST operates the Seoul Bio Hub business unit and provides research infrastructure, expertise, and program delivery including the growth support team.
• Korea UniversitycoreImplementation/ SI/ Consulting PartnerKorea University is one of the two operating institutions of Seoul Bio Hub (alongside KIST). The university contributes academic resources, hospital facilities (Korea University Anam Hospital), and research expertise to the hub ecosystem.
• Bio USAminorStrategic or Co-development PartnerEight startup companies from Seoul Biohub participated at BIO USA 2026 and achieved global partnership results. Seoul Bio Hub supports startups' international partnering activities at major global biotech conferences.
• KMDF (범부처의료기기연구개발사업단)minorStrategic or Co-development PartnerKMDF (Cross-ministerial Medical Device R&D Program) is listed as a cooperating institution for the Seoul-Roche Diagnostics Startup Sprint Demo Day program alongside Seoul Bio Hub and Roche Diagnostics.
• Electronic NewsminorGTM or Marketing PartnerElectronic News is a cooperating media partner for the Seoul-Roche Diagnostics Startup Sprint Demo Day, responsible for distributing press coverage of the event and selected companies.

Scale indicators3 records

Recent moves8 records

Expansion highlights7 records

Regional players

• Suzhou BioBAY: BioBAY is a major biotech cluster in Suzhou, China hosting 500+ biotech companies with government backing and shared infrastructure — the most direct regional analogue to Seoul Bio Hub as an Asia-based, government-supported biotech innovation cluster.
• Shanghai Zhangjiang Hi-Tech Park (Biotech Zone): Zhangjiang is China's largest biotech cluster, hosting multinational pharma R&D centers alongside domestic startups with government support — a regional analogue competing for Asian biotech talent and capital.
• Biopolis (A*STAR) Singapore: Biopolis is Singapore's flagship biomedical research hub, integrating A*STAR research institutes with pharma and biotech companies under a government-backed cluster model — highly comparable to Seoul Bio Hub's role within the Hongneung cluster anchored by KIST and Korea University.

Emerging players

• IndieBio: IndieBio is a global biotech accelerator providing seed funding, lab space, and mentorship to biology-based startups — comparable as a startup-focused biotech platform but with a venture-backed rather than government-backed operating model.

Direct peers

• BioGenerator: BioGenerator is a St. Louis-based biotech startup creator and investor that operates lab space, provides seed funding, and supports entrepreneur-residents — comparable mission-driven nonprofit biotech support organization.
• LabCentral: LabCentral operates shared laboratory and office facilities in Cambridge, MA for high-potential biotech startups, with a comparable model of shared research infrastructure, equipment access, and corporate sponsorship from pharma partners — closely aligned with Seoul Bio Hub's TREE infrastructure platform.
• Biolabs (Biolabs International): Biolabs operates a global network of coworking life science laboratories across the U.S. and Europe with shared equipment and corporate partnerships — a directly comparable shared-lab incubator model targeting biotech startups.
• Johnson & Johnson Innovation – JLABS: JLABS is a global network of life science incubators operated by J&J Innovation, providing no-strings-attached lab space, mentorship, and programming to early-stage biotech startups — directly analogous to Seoul Bio Hub's pharma-backed open innovation model with shared infrastructure.
• MBC BioLabs: MBC BioLabs runs shared lab incubators in San Carlos and San Jose, CA, offering biotech startups affordable lab space and access to capital and corporate partners — comparable shared-infrastructure incubator model for early-stage biotech.

Broad incumbents

• Alexandria LaunchLabs: Alexandria LaunchLabs provides branded coworking and accelerator facilities for life science startups within Alexandria Real Estate's broader life science property portfolio — a broader commercial real estate-backed incubator model with overlapping target customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/SeoulBiohub
• Facebookfacebook.com/seoulbiohub
• LinkedInlinkedin.com/company/seoulbiohub

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seoul Bio Hub